[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637658":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":21,"responsibleParty":37,"collaborators":10,"id":39,"slug":10,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":10,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Innopeutics Corporation","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"The group that received IPS101A",null,"The group of subjects who received IPS101A in the IPS101A-10 clinical trial",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"ChoLong Park","CONTACT","+82-2-3499-4266","clpark@innopeutics.com",{"name":19,"role":15,"phone":10,"phoneExt":10,"email":20},"Tae-gyun Kim","contact@innopeutics.com",[22],{"facility":23,"status":24,"city":25,"state":10,"zip":10,"country":26,"countryCode":10,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Severance Hospital","RECRUITING","Seoul","South Korea",{"type":28,"coordinates":29},"Point",[30,31],126.9784,37.566,{"lat":31,"lon":30},[34],{"name":35,"role":15,"phone":10,"phoneExt":10,"email":36},"Professor, MD, PhD","phlee@yuhs.ac",{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100637658",false,"NCT07629115","A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.","A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product in the IPS101A-10 Phase I Clinical Trial","Inclusion Criteria\n\n* Subjects who were enrolled in the IPS101A-10 clinical trial and received IPS101A.\n* Subjects and\u002For their legally acceptable representatives who voluntarily provided written informed consent to participate in this long-term follow-up study after being fully informed of the study, and who agreed to comply with all study-related requirements.\n\nExclusion Criteria\n\n* Subjects who decline to provide consent for participation in the long-term follow-up study, or for whom follow-up assessments are not feasible due to death or other reasons.\n* Subjects who, in the judgment of the investigator, are considered unsuitable for participation in the study due to unwillingness or inability to comply with scheduled study visits or other study-related requirements.","ALL","50 Years","80 Years",{"count":49,"type":50},6,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.",[54,55],"Parkinson Disease","Parkinson's Disease",[57,58,59],"Adeno-associated Virus","Gene therapy","AAV","2026-06-29",{"date":62,"type":63},"2026-07-01","ACTUAL",{"date":65,"type":63},"2026-05-29",{"date":67,"type":50},"2031-10-30",{"name":5,"class":6},1]